Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Total Non-current Assets
All assets not expected to be converted to cash within one year.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 19.0% from a year ago
Total non-current assets stood at $17.22M at the end of Q1 FY2026, down 19.0% from a year earlier and down 5.8% from the prior quarter. Over 3 fiscal years it compounded at -13.6% a year.
Context
- Total non-current assets amounted to 16.2% of total assets at the end of Q1 FY2026, up 5.1 pp from a year earlier.
- Total non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -19.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 18.27M USD
- Year-over-year change
- -12.8%
- 4-year CAGR
- +24.4%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.27M | -12.8% |
| FY2024 | 2024-12-31 | 20.95M | -17.2% |
| FY2023 | 2023-12-31 | 25.29M | -10.9% |
| FY2022 | 2022-12-31 | 28.38M | +271.5% |
| FY2021 | 2021-12-31 | 7.64M | — |
Total Non-current Assets vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -19.0% is the 7th highest of 9, against a peer median of -11.0%.
- Total non-current assets amounts to 16.2% of total assets for ARTV, versus a peer median of 11.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $35.2M USD | -16.8% | -3.0% | 24.5% | |
| Mar 2026 | $34.97M USD | -15.0% | -29.4% | 13.8% | |
| Mar 2026 | $33.47M USD | -7.0% | +53.6% | 33.7% | |
| Mar 2026 | $32.76M USD | +78.4% | -38.4% | 18.4% | |
| Mar 2026 | $21.02M USD | -38.2% | -24.8% | 8.7% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $17.22M USD | -19.0% | -13.6% | 16.2% |
| Mar 2026 | $8.37M USD | -22.3% | -25.6% | 8.2% | |
| Dec 2025 | $5.15M USD | +19.0% | -34.4% | 9.2% | |
| Mar 2026 | €1.49M EUR | +7.6% | -31.8% | 3.1% | |
| Peer median (excluding ARTV) | — | -11.0% | -27.5% | 11.5% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 160.92M | 102.53M | 53.5M | 40.24M | 26.7M |
| Short-term Investments | 0 | 0 | 23.47M | 145.19M | 81.31M |
| Net Receivables | 468K | 525K | 1.76M | 146K | 767K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.62M | 1.09M | 3.06M | 3.89M |
| Total Current Assets | 162.29M | 104.68M | 79.82M | 188.63M | 112.67M |
| Property, Plant & Equipment (Net) | 4.08M | 27.62M | 24.64M | 20.43M | 17.36M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 245K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.56M | 517K | 650K | 525K | 919K |
| Total Non-current Assets | 7.64M | 28.38M | 25.29M | 20.95M | 18.27M |
| Total Assets | 169.93M | 133.05M | 105.11M | 209.58M | 130.94M |
| Account Payables | 1.44M | 1.1M | 614K | 1.12M | 355K |
| Short-term Debt | 0 | 0 | 0 | 0 | 3.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.3M | 10.89M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 2.1M |
| Total Current Liabilities | 19.31M | 25.63M | 12.23M | 12.25M | 13.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 7.88M |
| Deferred Tax Liabilities | 216.41M | 216.41M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 21.68M | 15.64M | 0 | 0 | 0 |
| Other Non-current Liabilities | 81K | 115K | 241.59M | 73K | 0 |
| Total Non-current Liabilities | 239.48M | 248.13M | 254.9M | 10.69M | 7.88M |
| Total Liabilities | 258.78M | 273.75M | 267.13M | 22.94M | 20.97M |
| Common Stock | 0 | 0 | 0 | 3K | 3K |
| Retained Earnings | (93.8M) | (152.59M) | (181.31M) | (246.68M) | (330.55M) |
| Accumulated OCI | 0 | 0 | 308K | (129K) | 103K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (88.86M) | (140.7M) | (162.02M) | 186.64M | 109.97M |
| Total Debt | 1.74M | 19.45M | 16.91M | 14.35M | 10.94M |
| Net Debt | (159.18M) | (83.08M) | (36.59M) | (25.88M) | (15.76M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.